Journal
PEDIATRIC RHEUMATOLOGY
Volume 10, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/1546-0096-10-30
Keywords
Juvenile idiopathic arthritis; Macrophage activation syndrome; Tocilizumab
Categories
Funding
- NIAID NIH HHS [K08 AI072023] Funding Source: Medline
Ask authors/readers for more resources
Tocilizumab (TCZ) is the first FDA-approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available